Vir Biotechnology Inc
VIR5.100USD
+0.070+1.39%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
704.12MCap. mercado
PérdidaP/E TTM
Más Datos de Vir Biotechnology Inc Compañía
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Información de la empresa
Símbolo de cotizaciónVIR
Nombre de la empresaVir Biotechnology Inc
Fecha de salida a bolsaOct 11, 2019
Director ejecutivoDr. Marianne De Backer, Ph.D.
Número de empleados408
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 11
Dirección1800 Owens Street
CiudadSAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94158
Teléfono14159064324
Sitio Webhttps://www.vir.bio/
Símbolo de cotizaciónVIR
Fecha de salida a bolsaOct 11, 2019
Director ejecutivoDr. Marianne De Backer, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
4.69K
-94.10%
Dr. Mark Eisner, M.D.
Dr. Mark Eisner, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Ms. Janet Napolitano, J.D.
Ms. Janet Napolitano, J.D.
Independent Director
Independent Director
--
--
Mr. Jason V. O'byrne
Mr. Jason V. O'byrne
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Vicki L. Sato, Ph.D.
Dr. Vicki L. Sato, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
4.69K
-94.10%
Desglose de ingresos
FY2024
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
74.20M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 5 de jun
Actualizado: jue., 5 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
SB Investment Advisers (UK) Limited
12.07%
BlackRock Institutional Trust Company, N.A.
10.40%
ARCH Venture Partners
9.34%
The Vanguard Group, Inc.
9.25%
GSK plc
6.19%
Other
52.75%
Accionistas
Accionistas
Proporción
SB Investment Advisers (UK) Limited
12.07%
BlackRock Institutional Trust Company, N.A.
10.40%
ARCH Venture Partners
9.34%
The Vanguard Group, Inc.
9.25%
GSK plc
6.19%
Other
52.75%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
28.96%
Investment Advisor/Hedge Fund
15.19%
Private Equity
13.70%
Venture Capital
10.23%
Hedge Fund
7.60%
Corporation
6.19%
Individual Investor
4.39%
Research Firm
1.90%
Foundation
1.13%
Other
10.73%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
530
124.95M
90.39%
-15.17M
2025Q1
571
125.80M
91.30%
-16.44M
2024Q4
568
122.14M
89.06%
-13.83M
2024Q3
554
118.76M
86.83%
-17.44M
2024Q2
572
119.53M
87.47%
-20.55M
2024Q1
564
122.68M
91.07%
-16.10M
2023Q4
577
121.87M
90.75%
-16.40M
2023Q3
578
123.93M
92.29%
-3.81M
2023Q2
574
125.10M
93.31%
+332.42K
2023Q1
568
121.09M
90.65%
+1.82M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
SB Investment Advisers (UK) Limited
16.68M
12.07%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.37M
10.4%
-298.87K
-2.04%
Mar 31, 2025
ARCH Venture Partners
12.92M
9.34%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
12.78M
9.25%
-323.13K
-2.47%
Mar 31, 2025
GSK plc
8.55M
6.19%
--
--
Apr 01, 2025
State Street Global Advisors (US)
5.73M
4.14%
+652.43K
+12.86%
Mar 31, 2025
Scangos (George A)
3.78M
2.73%
-550.77K
-12.72%
Apr 01, 2025
Dimensional Fund Advisors, L.P.
2.68M
1.94%
+768.95K
+40.14%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.30M
1.66%
+98.43K
+4.48%
Mar 31, 2025
OrbiMed Advisors, LLC
2.25M
1.63%
-970.37K
-30.15%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Genomics Immunology and Healthcare ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
Global X Genomics & Biotechnology ETF
0.57%
ALPS Medical Breakthroughs ETF
0.47%
Invesco NASDAQ Future Gen 200 ETF
0.46%
Invesco S&P SmallCap Health Care ETF
0.33%
Hypatia Women CEO ETF
0.18%
SPDR S&P Biotech ETF
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
WisdomTree US SmallCap Quality Growth Fund
0.09%
Ver más
iShares Genomics Immunology and Healthcare ETF
Proporción1.03%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.87%
Global X Genomics & Biotechnology ETF
Proporción0.57%
ALPS Medical Breakthroughs ETF
Proporción0.47%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.46%
Invesco S&P SmallCap Health Care ETF
Proporción0.33%
Hypatia Women CEO ETF
Proporción0.18%
SPDR S&P Biotech ETF
Proporción0.17%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.1%
WisdomTree US SmallCap Quality Growth Fund
Proporción0.09%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
